Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Data: Provenge significantly improves survival in advanced prostate cancer
June 17th, 2005
Dendreon Corp. (DNDN) announced that, as previously reported at the American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium in February, Provenge, the company's investigational immunotherapy for the treatment of prostate cancer, significantly improved survival in men with asymptomatic, metastatic androgen-independent (hormone-refractory) prostate cancer when compared to patients receiving placebo. The study was presented at the 2005 ASCO annual meeting by Eric J. Small, MD, professor of medicine and urology at the University of California, San Francisco, California. Small presented the final 3-year intent-to-treat analysis of the...
Source: Drug Week (2005-06-17)
|
